Karyopharm Therapeutics, Inc. (KPTI): חוב להון עצמי

The Karyopharm Therapeutics (KPTI) price chart on the GURU.Markets platform demonstrates a total debt-to-equity ratio of 0.00. This biopharmaceutical innovator develops unique XPO1 inhibitors to combat myeloma, leveraging a robust research foundation. Steady demand for biotechnology renders the asset a defensive asset, independent of macroeconomic trends. However, potential drug side effects or failed new trials create certain financial threats.

This ratio measures the proportion of debt relative to equity, determining the extent to which the financial stability of Karyopharm Therapeutics (KPTI) depends on external creditors. Optimizing costs for laboratory maintenance and contract manufacturing operations directly impacts the balance sheet structure, which is reflected in the company's debt leverage history and confirms the business's ability to fund research and development without a critical risk of bankruptcy.